TLX Stock Price and Chart — NASDAQ:TLX — TradingView

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Check out other big names from the same industry as TLX.

Financials

Performance

Revenue to profit conversion

Debt level and coverage

Earnings

Next:—

Technicals

Summarizing what the indicators are suggesting.

Neutral

SellBuy

Strong sellStrong buy